SUPRIYA - Supriya Lifesci.

📊 NSE: SUPRIYA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 13:55

💰 Financial Performance

Revenue Growth by Segment

The company reported revenue from operations of INR 200 crores for Q2 FY '26, representing a 20% year-on-year growth compared to INR 166 crores in Q2 FY '25. Sequentially, revenue grew by 38%. Historical revenue has grown from INR 3,912 million in FY21 to INR 6,965 million in FY25.

Geographic Revenue Split

Exports are the cornerstone of the business, accounting for 81% of total revenue in Q2 FY '26. Foreign exchange earnings for the year ended March 31, 2025, were INR 5,286 million compared to INR 4,498.14 million in the previous year.

Profitability Margins

The company reported a PAT of INR 50.43 crores for Q2 FY '26 with a PAT margin of 25.2%. For the half-year ended September 30, 2025, PAT stood at INR 85.22 crores. Management guides for a stabilized margin of 33%-35% in the midterm as products transition from semi-regulated to regulated markets.

EBITDA Margin

EBITDA for Q2 FY '26 was INR 73 crores, a 12% year-on-year increase and 41% sequential increase. The EBITDA margin for the quarter was 36%, which is in line with management guidance.

Capital Expenditure

Capital expenditure has increased significantly, with FY25 capex spend at INR 1,623 million. As of September 30, 2025, Capital Work in Progress (CWIP) stood at INR 1,725 million, up from INR 1,480 million in March 2025. Property, plant, and equipment were valued at INR 4,519 million.

Credit Rating & Borrowing

ICRA upgraded the short-term rating to [ICRA]A1 from [ICRA]A2+. The company maintains a healthy leverage profile with a Debt/Equity ratio of 0.01 as of FY25. Total equity stood at INR 10,818 million as of September 2025.

⚙️ Operational Drivers

Raw Materials

None

Import Sources

None

Key Suppliers

None

Capacity Expansion

None

Manufacturing Efficiency

Management emphasizes 'execution excellence' and 'operational efficiency' as strategic levers to sustain growth and navigate operational challenges effectively.

📈 Strategic Growth

Expected Growth Rate

None

Growth Strategy

None

Products & Services

None

Brand Portfolio

None

New Products/Services

The company is launching new products in regulated markets and is bringing a finished formulation business on stream to add to margins.

Market Expansion

The strategy involves scaling up in semi-regulated markets and maturing products into regulated markets where entry barriers are higher and pricing is better.

Strategic growth analysis not yet available for this company.